Patrick Machado
CIK 1311210 · Chief Business Officer and CFO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MDVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94107
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALMS | Director | 10,617 | $6.66 | $70.7K | $0 | 4 | 2026-07-02 |
| RCUS | Director | 44,300 | $18.16 | $804.7K | $0 | 8 | 2026-06-12 |
| XENE | Director | 2,645 | $36.01 | $95.2K | $0 | 7 | 2026-06-03 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 0 | $4.36 | $0 | $214.4K | 15 | 2025-12-10 |
| ACELYRIN, Inc. (SLRN) Delisted | Director | 14,675 | $2.27 | $33.3K | $0 | 3 | 2024-06-11 |
| CHIMERIX INC (CMRX) Delisted | Director | 10,000 | $8.54 | $85.4K | $70.8K | 10 | 2023-06-12 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 3 | 2020-09-28 |
| Urovant Sciences Ltd. (UROV) Delisted | 10%+ Owner | 22,860,013 | $16.24 | $371.25M | $38.75M | 9 | 2019-06-19 |
| Myovant Sciences Ltd. (MYOV) Delisted | 10%+ Owner | 40,765,599 | $26.98 | $1.10B | $42.50M | 2 | 2019-06-06 |
| SCYX | Director | 750 | $3.86 | $2.9K | $165.4K | 7 | 2019-01-04 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-21 |
| ABUS | 10%+ Owner | — | $4.29 | — | $0 | 2 | 2018-01-16 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 2 | 2017-06-21 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 219,564 | — | — | -$54.43M | 52 | 2016-06-23 |
| MEDIVATION, INC. (MDV) Delisted | Sr. Vice President and CFO | 486,123 | $18.05 | $8.77M | -$178.0K | 1 | 2007-03-20 |
Recent Filings · Page 14 of 14
139 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-06-11 | MEDIVATION, INC. (MDVN) Delisted | Sell (S) | −10,000 | -$149.0K | EDGAR |
| 2008-03-05 | MEDIVATION, INC. (MDVN) Delisted | Sell (S) | −10,000 | -$156.3K | EDGAR |
| 2007-12-05 | MEDIVATION, INC. (MDVN) Delisted | Sell (S) | −10,000 | -$131.0K | EDGAR |
| 2007-10-18 | MEDIVATION, INC. (MDVN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-09-21 | MEDIVATION, INC. (MDVN) Delisted | Sell (S) | −10,000 | -$189.2K | EDGAR |
| 2007-07-24 | MEDIVATION, INC. (MDVN) Delisted | Gift (G) | −476,123 | $0 | EDGAR |
| 2007-07-17 | MEDIVATION, INC. (MDVN) Delisted | Gift (G) | −486,123 | $0 | EDGAR |
| 2007-06-07 | MEDIVATION, INC. (MDVN) Delisted | Sell (S) | −10,000 | -$166.7K | EDGAR |
| 2007-03-20 | MEDIVATION, INC. (MDV) Delisted | Sell (S) | −10,000 | -$178.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.